Sipagladenant

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H121096

CAS#: 858979-50-7

Description: Sipagladenant is an adenosine receptor A2A inverse agonist. Sipagladenant can be used in frontal lobe dysfunction research.

Chemical Structure

img
Sipagladenant
CAS# 858979-50-7
Instruction

Theoretical Analysis

Hodoodo Cat#: H121096
Name: Sipagladenant
CAS#: 858979-50-7
Chemical Formula: C20H19N3O4S
Exact Mass: 397.11
Molecular Weight: 397.450
Elemental Analysis: C, 60.44; H, 4.82; N, 10.57; O, 16.10; S, 8.07

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Sipagladenant; SCHEMBL879438; EX-A7778; KW-6356

IUPAC/Chemical Name: N-[4-(furan-2-yl)-5-(oxane-4-carbonyl)-1,3-thiazol-2-yl]-6-methylpyridine-3-carboxamide

InChi Key: KMFLQPJJHQNKKF-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H19N3O4S/c1-12-4-5-14(11-21-12)19(25)23-20-22-16(15-3-2-8-27-15)18(28-20)17(24)13-6-9-26-10-7-13/h2-5,8,11,13H,6-7,9-10H2,1H3,(H,22,23,25)

SMILES Code: O=C(C1=CC=C(C)N=C1)NC2=NC(C3=CC=CO3)=C(C(C4CCOCC4)=O)S2

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 397.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ohno Y, Suzuki M, Asada H, Kanda T, Saki M, Miyagi H, Yasunaga M, Suno C,
Iwata S, Saito JI, Uchida S. In Vitro Pharmacological Profile of KW-6356, a
Novel Adenosine A2A Receptor Antagonist/Inverse Agonist. Mol
Pharmacol. 2023 Jun;103(6):311-324. doi: 10.1124/molpharm.122.000633. Epub 2023
Mar 9. PMID: 36894319.

2: Maeda T, Kimura T, Sugiyama K, Yamada K, Hiraiwa R, Nishi M, Hattori N;
6356-002 study group. Randomized controlled trial of KW-6356 monotherapy in
patients with early untreated Parkinson's disease. Parkinsonism Relat Disord.
2023 Dec;117:105907. doi: 10.1016/j.parkreldis.2023.105907. Epub 2023 Oct 31.
PMID: 37948832.

3: Tayama T, Ishiuchi M, Sugiyama K, Oka Y, Maeda H, Nagata Y, Hruska M, Kagawa
Y. Safety, Tolerability, and Pharmacokinetics of the Novel Adenosine
A2A Antagonist/Inverse Agonist KW-6356 Following Single and Multiple
Oral Administration in Healthy Volunteers. Clin Pharmacol Drug Dev. 2023
Aug;12(8):801-809. doi: 10.1002/cpdd.1222. Epub 2023 Jan 22. PMID: 36683291.

4: Ohno Y, Okita E, Kawai-Uchida M, Shoukei Y, Soshiroda K, Kanda T, Uchida S.
The adenosine A2A receptor antagonist/inverse agonist, KW-6356
enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia
in MPTP-treated common marmosets. J Pharmacol Sci. 2023 Jul;152(3):193-199. doi:
10.1016/j.jphs.2023.05.001. Epub 2023 May 11. PMID: 37257947.

5: Ohno Y, Okita E, Kawai-Uchida M, Fukuda N, Shoukei Y, Soshiroda K, Yamada K,
Kanda T, Uchida S. Anti-parkinsonian activity of the adenosine A2A
receptor antagonist/inverse agonist KW-6356 as monotherapy in MPTP-treated
common marmosets. Eur J Pharmacol. 2023 Jul 5;950:175773. doi:
10.1016/j.ejphar.2023.175773. Epub 2023 May 3. PMID: 37146707.